



Coronavirus disease 2019 (COVID-19), caused by severe acute 
respiratory syndrome-coronavirus-2 (SARS-CoV-2), has been 
shown to present respiratory symptoms that include cough, 
fever and difficulty in breathing.[1] In addition to respiratory 
system involvement, COVID-19 due to SARS-CoV-2 may 
manifest with pathology related to hematologic, cardiovascular, 
renal, gastrointestinal and hepatobiliary, endocrinologic, 
neurologic, ophthalmologic, and dermatologic systems.[1,2] The 
pathophysiologic basis of the clinical features of COVID-19 
reflects both pulmonary and extra‑pulmonary dissemination and 
replication of SARS-CoV-2 or widespread immunopathologic 
perturbation or complication of the disease.[3,4] Various studies 
from several countries have reported a variety of clinical 
manifestations of COVID-19.[5] In Nigeria and most low- and 
middle-income countries, COVID-19 testing has largely 
focused on patients with respiratory symptoms, this is despite 
reports of extrapulmonary presentations.[4-6] Report on the 
clinical features of COVID-19 in a locality is desirable for a 
better understanding of the disease and appropriate triaging 
of cases. Missed or misdiagnosed cases could facilitate rapid 
dissemination of COVID-19 by unwittingly spreading the virus 
in both hospital and community setting where universal testing 
is unobtainable.[5,6] Patients without prominent respiratory 
symptoms may be a major driver of the ongoing COVID-19 
pandemic.[4,6] Studies have demonstrated the presence of 
SARS-CoV-2 RNA in gastrointestinal glandular epithelial 
cells. Intracellular staining of  salivary, gastric, duodenal, and 
rectal epithelia have also revealed SARS-CoV-2 nucleocapsid 
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protein. This finding indicates the virus infects these cells, and 
therefore may imply the possibility of transmissibility of virus 
other than via respiratory droplets.[5,7]
Given the various pulmonary and extrapulmonary 
manifestations of COVID-19, a report of clinical presentation 
in different localities is desirable. This study aimed to report 
the clinical characteristics of COVID-19 in a tertiary health 
institution in Northeast Nigeria.
Methodology
This study was conducted at the Federal Medical Centre 
Nguru, a tertiary health institution in Northeast Nigeria. The 
hospital is a designated treatment center for COVID-19. We 
reviewed the clinical records of 850 with clinical features 
suggestive of COVID-19 from March 14 to October 14, 
2020. We abstracted the records of 55 laboratory‑confirmed, 
symptomatic COVID-19 patients with documented clinical 
features of mild,/moderate, or severe disease for analysis. 
Information obtained included biodata, clinical presentations, 
vital signs, pulse oximetry, laboratory investigations, and pre-
existing health condition. The clinical spectrum of COVID-19 
due to SARS‑CoV‑2 infection was classified according to the 
Treatment Guidelines adopted from the WHO-China joint 
mission[8] and Emergency Response Team on COVID-19[9] 
as follows:
Asymptomatic or presymptomatic infection
Individuals who test positive for SARS-CoV-2 using a 
virologic test (i.e. a nucleic acid amplification test or an 
antigen test) but who have no symptoms that are consistent 
with COVID-19.
Mild illness
Individuals who have any of the various signs and symptoms of 
COVID-19 (e.g. fever, cough, sore throat, malaise, headache, 
muscle pain, nausea, vomiting, diarrhea, loss of taste and 
smell) but who do not have shortness of breath, dyspnea, or 
abnormal chest imaging.
Moderate illness
Individuals who show evidence of lower respiratory disease 
during clinical assessment or imaging and who have the 
saturation of oxygen (SpO2) ≥94% on room air at sea level.
Severe illness
Individuals who have SpO2 <94% on room air at sea level, 
the ratio of arterial partial pressure of oxygen to fraction 
of inspired oxygen (PaO2/FiO2) <300 mm Hg, respiratory 
frequency >30 breaths/min, or lung infiltrates >50%.
Critical illness
Individuals who have respiratory failure, septic shock, and/or 
multiple organ dysfunctions.
COVID‑19 infection was confirmed based on real‑time reverse 
transcriptase-polymerase chain reaction (rRT-PCR) assay for 
nasal and pharyngeal swab specimens. RNA was extracted 
from clinical specimens and determined by rRT-PCR targeting 
the open reading frame 1ab gene of SARS-CoV-2.[1]
Statistical analysis
Categorical variable results are presented as numbers 
and percentages. Continuous variables are presented as 
mean ± standard deviation (SD), means, maximums, and 
minimums as appropriate. Chi-squared (or Fisher’s exact) 
tests were used for categorical variables. Statistical analysis 
was performed using IBM SPSS Statistics software 
(version 20.0; IBM, Armonk, NY, USA). A significance level 
of P < 0.05 was used.
results
Fifty-f ive symptomatic COVID-19 patients  were 
evaluated in this study. Their mean age was 49.1 ± 16.3 
(females 51.4 ± 15.6, males 48.5 ± 17.2, P = 0.601) 
with females constituting 47.2% of the studied patients. 
Table 1 shows the presenting symptoms of these patients. 
Fever (87.3%), cough (67.3%), sore throat (49.1%), and 
rhinorrhea (41.8%) were the most common clinical feature. 
Other features included difficulty in breathing (25.5%) 
and ageusia (14.6%). Gastrointestinal symptoms such 
as diarrhea, vomiting, and abdominal pain were seen in 
10.9%, 18.2%, and 9.1%, respectively [Table 1]. Of the 
studied patients, 21 (8 females, 13 males) had preexisting 
health conditions. The mean capillary oxygen saturation at 
room air (SPO2) of patients was 93.4 (SD, 17.2). Table 2 
Table 2: The proportion of preexisting health condition 
and mean capillary oxygen saturation
n (%)
Sex, female 8
Mean SPO2 at presentation 93.4 (17.2)





SPO2: Oxygen saturation at room air
Table 1: Clinical features of coronavirus disease 2019
n (%)
Cough 37 (67.3)
Sore throat 27 (49.1)
Fever 48 (87.3)
Difficulty in breathing 14 (25.5)
Running nose 23 (41.8)
Vomiting 10 (18.2)
Nausea 8 (14.6)
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depicts the proportion of pre-existing health condition and 
mean capillary oxygen saturation. Twenty‑one (38.2%) 
patients had a pre-existing health condition. The distribution 
of patients across a defined age group is as depicted in 
Figure 1. Patients aged 36–45 years constituted 21.8%, 
while 10.9% were older than 65 years. Figure 2 shows the 
stratification of the participants based on occupation. House 
wives constituted 38% of the studied population. Figure 3 
depicts the proportion of pre-existing/comorbid health 
conditions. Chronic kidney disease was the most common; 
it was seen in 34% of patients; other common conditions 
included hypertensive heart disease (24%) and diabetes 
mellitus (16%).
The comparison of gender variation, clinical features and 
proportion of pre-existing health condition(s) in this study, and 
two similar previous reports is presented in Table 3.
There was a significant variation in the proportion of 
participants with respect to gender (P = 0.026) in the three 
studies. Similarly, there was a statistically significant 
difference in the proportion of patients that presented with 
fever (P = 0.021), diarrhea (P = 0.035), and shortness of 
breath (P = 0.000) across all three studies. There was no 
observed significant variation in the proportion of patients 
that presented with fever (P = 0.071) and diarrhea (P = 0.137) 
between this study and Huang et al. However, there was a 
statistically significant variation in the proportion of patients 
that presented with difficulty in breathing (P = 0.000), between 
this study and Chen et al. [Table 3].
dIscussIon
Fever 87.3%, cough 67.3%, sore throat (49.1%), 
rhinorrhea (41.8%), and difficulty in breathing (25.5%) were 
the common feature of COVID‑19 in this study. Our finding is 
similar to previous studies that reported respiratory symptoms 
as the most common manifestation of COVID-19.[7-9] The 
clinical feature of COVID-19 has been reported to vary 
widely, but often resembles viral pneumonia, and the severity 
of illness ranges from mild to severe. Earlier studies have 
reported clinical manifestations to include non‑specific mild 
symptoms such as anorexia, confusion, dizziness, sore throat, 
rhinorrhea, and sputum production.[6-9] Approximately 80% of 
patients have been reported to present with mild illness, 14% 
present with severe illness, and 5% present with a critical 
illness.[8,9]
COVID-19, is a potentially severe acute respiratory 
infection caused by SARS-CoV-2. SARS-CoV-2 RNA 
virus has been detected from a nasopharyngeal aspirate of 
COVID-19 patients.[4,9] The tissues of the respiratory tract, such 
as oral and nasal mucosa and nasopharynx, is endowed with 
angiotensin-converting enzyme 2 receptor, which serves as a 
Table 3: Intergroup comparison between this study and two similar publications
Characteristics This study 
(55 cases)
Huang et al.[10] 
(49 cases)




Age, n (%) 49.1 (16.3) 49 (17.0) 55.5 (17.7) -
Sex, female, n (%) 28/55 (47.2) 11/41 (27) 32 (32.0) 0.026®
Preexisting health condition, n (%) 21/55 (38.2) 13/41 (32) 50 (51) 0.085
Fever, n (%) 48/55 (87.3) 40/41 (98) 82 (83) 0.021β
Cough, n (%) 37/55 (67.3) 31/41 (76.0) 81 (82) 0.124
Difficulty in breathing/shortness of breath, n (%) 14/55 (25.5) 22/40 (55) 31 (31) 0.000∞
Diarrhoea, n (%) 6/55 (10.9) 1/38 (3) 2 (2) 0.035¥
®This study versus Huang 0.017; this study versus Chen 0.001; Huang versus Chen 0.018, βThis study versus Huang 0.071; this study versus Chen 0.466; 
Huang versus Chen 0.018, ∞This study versus Huang 0.003; this study versus Chen 0.444; Huang versus Chen 0.000, ¥This study versus Huang 0.137; this 
study versus Chen 0.017; Huang versus Chen 0.827. The difference between groups was calculated by Fisher’s exact test in R software
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Figure 1: Age distribution of the studied patients
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receptacle for SARS-CoV-2. Although coronavirus’s primary 
target is the respiratory tract, it is known to involve other 
systems such as extrapulmonary manifestations.[7-9]
The SARS CoV-2 has been detected from other sites indicating 
the possibility of its transmission in ways other than respiratory 
droplets. The extrapulmonary pathology of COVID-19 could be 
due to either extrapulmonary dissemination of the virus and its 
replication or widespread immune-pathological complications 
of the disease.[5,6,9] The incidence of gastrointestinal 
manifestation of COVID-19 has been reported to range 
from 12% to 61%.[12,13] In a meta-analysis of 29 studies, the 
pooled prevalence of individual symptoms reported was 
anorexia (21%), nausea and/vomiting (7%), diarrhea (9%), 
and abdominal pain (3%).[14] In this study, vomiting (18.2%) 
was the most common gastrointestinal symptom; others 
included diarrhea (10.9%), nausea (14.6%), and abdominal 
pain (9.1%). A higher prevalence of gastrointestinal 
symptoms was reported from a study conducted in the USA 
(anorexia, 34.8%, diarrhea, 33.7%, and nausea, 26.4%).[15] 
Furthermore, a study has shown that the presence of gastrointestinal 
symptoms at presentation to be associated with a 70% 
increased risk of the detection of SARS-CoV-2.[16] However, 
gastrointestinal bleeding appears to be a rare feature of 
COVID-19, despite the possible risk of bleeding from 
prolonged mechanical ventilation, thrombocytopenia or 
the use of systemic anticoagulation.[16] Preexisting health 
conditions (e.g. hypertension, diabetes, cardiovascular 
disease) were mostly seen in patients aged >45 years, who 
also constituted the majority (91.4%) of patients in this 
study. Our finding is similar to previous studies that reported 
a higher incidence of both comorbidities and the disease in 
older patients.[17-19]
The clinical features of COVID-19 have been shown to vary 
in several reports.[10,11,20] We compared the incidences in this 
report and findings from two similar studies.[10,11] We found 
that the incidence of fever (P = 0.021), diarrhea (P = 0.035), 
and shortness of breath (P = 0.000) showed a statistically 
significant difference across the studies. The proportion 
of patients that presented with fever (P = 0.071) and 
diarrhea (P = 0.137) between this study and Huang 
et al.[10] were comparable. Conversely, there was a statistically 
significant difference in the proportion of patients that 
presented with fever (P = 0.001) in this study and Chen 
et al.[11] The wide variation in the clinical pattern of 
presentation in different setting suggests that COVID‑19 has 
a broad spectrum of manifestation.
Limitations of the study
Although large enough to conduct valid comparisons with 
similar previous reports, the sample size used in this study 
remains limited; larger studies should be performed to further 
characterize clinical features in COVID-19 patients. The 
retrospective design of this study has the potential for bias. 
Nonetheless, we made systematic efforts to obtain a thorough 
and detailed history from the medical record of each patient 
in this study.
conclusIon
Respiratory symptoms are the most presentation of COVID-19 
in our setting. However, some patients also presented with 
additional extrapulmonary symptoms. A significant proportion, 
38.2%, of symptomatic COVID‑19 patients had preexisting 
health conditions in this study.
Recommendation
The extrapulmonary features of COVID-19, as observed in 
this study, underscore the need to consider expanding the 
case definition.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
references
1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics 
of 138 hospitalized patients with 2019 novel coronavirus-infected 
pneumonia in Wuhan, China. JAMA 2020;323:1061-9.
2. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, 
et al. Extrapulmonary manifestations of COVID-19. Nat Med 
2020;26:1017-32.
3. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and 
serological investigation of 2019-nCoV infected patients: Implication of 
multiple shedding routes. Emerg Microbes Infect 2020;9:386-9.
4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization 
and epidemiology of 2019 novel coronavirus: Implications for virus 
origins and receptor binding. Lancet 2020;395:565-74.
5. Arawomo AO, Ajibade AI, Adeniyi B, Aigbirior J, Erhabor GE. 
Coronavirus disease 2019 (COVID-19): Clinical perspectives and 
ongoing challenges. West Afr J Med 2020;37:295-316.
6. Africa CDC. Outbreak Brief: Coronavirus 2019 (COVID-19) Pandemic. 
Africa CDC: Centre for Disease Control and Prevention; 2010. p. 1-7.
7. Parasa S, Desa MI, Chandrasekar VT, Pate HK, Kennedy KF, et al. 
Prevalence of gastrointestinal symptoms and fecal viral shedding 
in patients with coronavirus disease 2019. A systematic review and 
Figure 3: The propor tion of comorbidities in studied par ticipants. 
CKD (Chronic Kidney Disease), DM (Diabetes Melliatus), HHD 
(Hypertensive Heart Disease), IDH (Ischaemic Heart Disease), PTB 
(Pulmonary Tuberculosis), PPCM (Peripartum Cardiomyopathy), UTI 
(Urinary Tract Infection)
Denue, et al.: Clinical characteristics of COVID 19
Nigerian Journal of Medicine ¦ Volume 30 ¦ Issue 3 ¦ May-June 2021338
meta-analysis. JAMA Netw Open. 2020;3:e2011335. doi: 10.1001/
jamanetworkopen.2020.11335.
8. Novel Coronavirus Pneumonia Emergency Response Epidemiology 
Team. The epidemiological characteristics of an outbreak of 2019 novel 
coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing 
Xue Za Zhi 2020;41:145-51.
9. Aylward B, (WHO); Liang W (PRC). Report of the WHO-China Joint 
Mission on Coronavirus Disease 2019 (COVID-19). 16 – 24th February 
2020.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Chu H, Hu Y, et al. Clinical 
features of patients infected with 2019 novel coronavirus in Wuhan, 
China. Lancet 2020;395:497-506.
11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological 
and clinical characteristics of 99 cases of 2019 novel coronavirus 
pneumonia in Wuhan, China: A descriptive study. Lancet 
2020;395:507-13.
12. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan L, et al. Clinical characteristics 
of COVID-19 patients with digestive symptoms in Hubei, China: 
A descriptive, cross-sectional, multicenter study. Am J Gastroenterol 
2020;115:766-73.
13. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of 
lopinavir-ritonavir in adults hospitalized with severe COVID-19. 
N Engl J Med 2020;382:1787-99.
14. Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations 
and prognosis of gastrointestinal and liver involvement in patients 
with COVID-19: A systematic review and meta-analysis. Lancet 
Gastroenterol Hepatol 2020;5:667-78.
15. Pointner H, Flegel U. Treatment of exocrine pancreatic insufficiency with 
fungal lipase (author’s transl). Arzneimittelforschung 1975;25:1833-5.
16. Nobel YR, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, 
et al. Gastrointestinal symptoms and COVID-19: Case-control study 
from the United States. Gastroenterology 2020;159:373-5.e2. doi: 
10.1053/j.gastro.2020.04.017.
17. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. 
Characteristics and outcomes of 21 critically ill patients with COVID-19 
in Washington State. JAMA 2020;323:1612-4.
18. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics 
of patients dying in relation to COVID-19 in Italy. JAMA 
2020;323:1775-6.
19. Wu Z, McGoogan JM. Characteristics of and important lessons from the 
coronavirus disease 2019 (COVID-19) outbreak in China: Summary of 
a report of 72 314 cases from the Chinese center for disease control and 
prevention. JAMA 2020;323:1239-42.
20. Chan JF, Yuan S, Wang KK, Chu H, Yang J, Zhang L, et al. A familial 
cluster of pneumonia associated with the 2019 novel coronavirus 
indicating person-to-person transmission: A study of a family cluster. 
Lancet 2020;395:514-23.
